Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Sponsor
Anhui Provincial Hospital
Study ID
NCT03546855
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg/d po,28 days as one cycle

Study Details

To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Key Dates

Start date
Jun 1, 2018
Status verified
May 2018
Primary completion
Dec 1, 2019
Completion
Jun 1, 2020

Study Design

Enrollment
69 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    apatinib 500mg/d po.28d as one cycle

Primary Outcome Measure

Apatinib treating patients with advanced cervical cancer after radiotherapy and first-line chemotherapy. [ Time Frame: 12 week ]

Related Studies